Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.

Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial

Open access

Abstract

The SELECT trial previously reported a 20% reduction in major adverse cardiovascular events with semaglutide ( n = 8,803) versus placebo ( n = 8,801) in patients with overweight/obesity and established cardiovascular disease, without diabetes. In the present study, we examined the effect of once-weekly semaglutide 2.4 mg on kidney outcomes in the SELECT trial. The incidence of the pre-specified main composite kidney endpoint (death from kidney disease, initiation of chronic kidney replacement therapy, onset of persistent estimated glomerular filtration rate (eGFR) < 15 ml min −1 1.73 m − 2 , persistent ≥50% reduction in eGFR or onset of persistent macroalbuminuria) was lower with semaglutide (1.8%) versus placebo (2.2%): hazard ratio (HR) = 0.78; 95% confidence interval (CI) 0.63, 0.96; P = 0.02. The treatment benefit at 104 weeks for eGFR was 0.75 ml min −1 1.73 m − 2 (95% CI 0.43, 1.06; P < 0.001) overall and 2.19 ml min −1 1.73 m − 2 (95% CI 1.00, 3.38; P < 0.001) in patients with baseline eGFR <60 ml min −1 1.73 m − 2 . These results suggest a benefit of semaglutide on kidney outcomes in individuals with overweight/obesity, without diabetes. ClinicalTrials.gov identifier: NCT03574597 .

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-024-03015-5

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Time to first occurrence of the main 5-component kidney composite endpointa. Data are the observed (that is, as measured) probability of patients experiencing their first occurrence of the main 5-component kidney composite endpoint during the in-trial period, analyzed using the Kaplan–Meier method, and the estimated HR, analyzed using a Cox regression model. Tied events were handled using the Exact method, if possible, or Efron’s method, if not. Numbers below the graph are the number of patients at risk. P values are two-sided and were not adjusted for multiplicity. a The main 5-component kidney composite endpoint included death from kidney causes, initiation of chronic kidney replacement therapy (dialysis or transplantation), onset of persistent eGFR <15 ml min−1 1.73 m−2, persistent ≥50% reduction in eGFR compared to baseline or onset of persistent macroalbuminuria.
Fig. 1 Time to first occurrence of the main 5-component kidney composite endpointa. Data are the observed (that is, as measured) probability of patients experiencing their first occurrence of the main 5-component kidney composite endpoint during the in-trial period, analyzed using the Kaplan–Meier method, and the estimated HR, analyzed using a Cox regression model. Tied events were handled using the Exact method, if possible, or Efron’s method, if not. Numbers below the graph are the number of patients at risk. P values are two-sided and were not adjusted for multiplicity. a The main 5-component kidney composite endpoint included death from kidney causes, initiation of chronic kidney replacement therapy (dialysis or transplantation), onset of persistent eGFR <15 ml min−1 1.73 m−2, persistent ≥50% reduction in eGFR compared to baseline or onset of persistent macroalbuminuria.CC BY · PubMed Central
Fig. 2 Effect of semaglutide 2.4 mg on the main 5-component kidney composite endpoint. Data are the observed (that is, as measured) n (%) of patients experiencing the first event that contributed to the main 5-component kidney composite endpoint from the in-trial observation period and the HR, and 95% CI was estimated using a Cox regression model. The symbols are the HRs, and the error bars are the 95% CIs. P values are two-sided and were not adjusted for multiplicity. a Dialysis or kidney transplantation. b Percent reduction is defined from baseline; the denominator is, therefore, reduced because of patients missing a baseline score. N/A, not applicable.
Fig. 2 Effect of semaglutide 2.4 mg on the main 5-component kidney composite endpoint. Data are the observed (that is, as measured) n (%) of patients experiencing the first event that contributed to the main 5-component kidney composite endpoint from the in-trial observation period and the HR, and 95% CI was estimated using a Cox regression model. The symbols are the HRs, and the error bars are the 95% CIs. P values are two-sided and were not adjusted for multiplicity. a Dialysis or kidney transplantation. b Percent reduction is defined from baseline; the denominator is, therefore, reduced because of patients missing a baseline score. N/A, not applicable.CC BY · PubMed Central
Fig. 3 Effect of semaglutide 2.4 mg on the main 5-component kidney composite endpointa by subgroup. Data are the observed (that is, as measured) n (%) of patients experiencing their first occurrence of the main 5-component kidney composite endpoint from the in-trial observation period and the HR, and 95% CI was estimated using a Cox regression model, assessed according to patient baseline characteristics. The symbols are the HRs, and the error bars are the 95% CIs. a The main 5-component kidney composite endpoint included death from kidney causes, initiation of chronic kidney replacement therapy (dialysis or transplantation), onset of persistent eGFR <15 ml min−1 1.73 m−2, persistent ≥50% reduction in eGFR compared to baseline or onset of persistent macroalbuminuria. b P value for the treatment difference by subgroup. Interaction P values were calculated using the score test. P values are two-sided and were not adjusted for multiplicity. c Ischemic or hemorrhagic stroke. d A combination of two or more events. CVA, cardiovascular accident; PAD, peripheral artery disease.
Fig. 3 Effect of semaglutide 2.4 mg on the main 5-component kidney composite endpointa by subgroup. Data are the observed (that is, as measured) n (%) of patients experiencing their first occurrence of the main 5-component kidney composite endpoint from the in-trial observation period and the HR, and 95% CI was estimated using a Cox regression model, assessed according to patient baseline characteristics. The symbols are the HRs, and the error bars are the 95% CIs. a The main 5-component kidney composite endpoint included death from kidney causes, initiation of chronic kidney replacement therapy (dialysis or transplantation), onset of persistent eGFR <15 ml min−1 1.73 m−2, persistent ≥50% reduction in eGFR compared to baseline or onset of persistent macroalbuminuria. b P value for the treatment difference by subgroup. Interaction P values were calculated using the score test. P values are two-sided and were not adjusted for multiplicity. c Ischemic or hemorrhagic stroke. d A combination of two or more events. CVA, cardiovascular accident; PAD, peripheral artery disease.CC BY · PubMed Central
Fig. 4 Effect of semaglutide 2.4 mg on changes in eGFR and UACR over time in the overall population. Data are estimated mean (CI) changes from the estimated baseline value in eGFR (a) and UACR (b), analyzed using an MMRM. The change in UACR was analyzed as the estimated mean ratio to baseline; for ease of interpretation; these ratios were converted to relative percentage changes from baseline using the formula (estimated ratio − 1) × 100. Numbers below the graphs are the number of patients contributing to the analysis. a Given gradual entry to the trial across the enrolment period and variable follow-up duration, data at 156 weeks and 208 weeks are sparser compared to previous timepoints.
Fig. 4 Effect of semaglutide 2.4 mg on changes in eGFR and UACR over time in the overall population. Data are estimated mean (CI) changes from the estimated baseline value in eGFR (a) and UACR (b), analyzed using an MMRM. The change in UACR was analyzed as the estimated mean ratio to baseline; for ease of interpretation; these ratios were converted to relative percentage changes from baseline using the formula (estimated ratio − 1) × 100. Numbers below the graphs are the number of patients contributing to the analysis. a Given gradual entry to the trial across the enrolment period and variable follow-up duration, data at 156 weeks and 208 weeks are sparser compared to previous timepoints.CC BY · PubMed Central
Fig. 5 Effect of semaglutide 2.4 mg on changes in eGFR and UACR over time by subgroup. Data are estimated mean (CI) changes from the estimated baseline value in eGFR (a) and UACR (b), analyzed using an MMRM. The change in UACR was analyzed as the estimated mean ratio to baseline; for ease of interpretation, these ratios were converted to relative percentage changes from baseline using the formula (estimated ratio − 1) × 100. Darker lines are used for the larger subgroups. Numbers below the graphs are the number of patients contributing to the analysis. Changes in UACR by baseline UACR subgroup at 208 weeks are not presented because of small patient numbers. a Given gradual entry to the trial across the enrollment period and variable follow-up duration, data at 156 weeks and 208 weeks are sparser compared to previous timepoints.
Fig. 5 Effect of semaglutide 2.4 mg on changes in eGFR and UACR over time by subgroup. Data are estimated mean (CI) changes from the estimated baseline value in eGFR (a) and UACR (b), analyzed using an MMRM. The change in UACR was analyzed as the estimated mean ratio to baseline; for ease of interpretation, these ratios were converted to relative percentage changes from baseline using the formula (estimated ratio − 1) × 100. Darker lines are used for the larger subgroups. Numbers below the graphs are the number of patients contributing to the analysis. Changes in UACR by baseline UACR subgroup at 208 weeks are not presented because of small patient numbers. a Given gradual entry to the trial across the enrollment period and variable follow-up duration, data at 156 weeks and 208 weeks are sparser compared to previous timepoints.CC BY · PubMed Central
Extended Data Fig. 1 Effect of semaglutide 2.4 mg on changes in eGFR over time by baseline UACR. Data are estimated mean (CI) changes from the estimated baseline value in eGFR, analysed using a mixed model for repeated measurements. Darker lines are used for the larger subgroups. CI, confidence interval; eGFR, estimated glomerular filtration rate; UACR, urinary albumin-to-creatinine ratio.
Extended Data Fig. 1 Effect of semaglutide 2.4 mg on changes in eGFR over time by baseline UACR. Data are estimated mean (CI) changes from the estimated baseline value in eGFR, analysed using a mixed model for repeated measurements. Darker lines are used for the larger subgroups. CI, confidence interval; eGFR, estimated glomerular filtration rate; UACR, urinary albumin-to-creatinine ratio.CC BY · PubMed Central
Extended Data Fig. 2 Effect of semaglutide 2.4 mg on changes in UACR over time by baseline eGFR. Data are estimated mean (CI) changes from the estimated baseline value in UACR, analysed using a mixed model for repeated measurements. The change in UACR was analysed as the estimated mean ratio to baseline; for ease of interpretation, these ratios have been converted to relative percentage changes from baseline using the formula (estimated ratio − 1) × 100. Darker lines are used for the larger subgroups. Numbers below the graphs are the number of patients contributing to the analysis. CI, confidence interval; eGFR, estimated glomerular filtration rate; UACR, urinary albumin-to-creatinine ratio.
Extended Data Fig. 2 Effect of semaglutide 2.4 mg on changes in UACR over time by baseline eGFR. Data are estimated mean (CI) changes from the estimated baseline value in UACR, analysed using a mixed model for repeated measurements. The change in UACR was analysed as the estimated mean ratio to baseline; for ease of interpretation, these ratios have been converted to relative percentage changes from baseline using the formula (estimated ratio − 1) × 100. Darker lines are used for the larger subgroups. Numbers below the graphs are the number of patients contributing to the analysis. CI, confidence interval; eGFR, estimated glomerular filtration rate; UACR, urinary albumin-to-creatinine ratio.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 62 references

Cited by

See all 238

Metadata

Authors
Colhoun, H. M., Lingvay, I., Brown, P. M., Deanfield, J., Brown-Frandsen, K., Kahn, S. E., Plutzky, J., Node, K., Parkhomenko, A., Rydén, L., Wilding, J. P. H., Mann, J. F. E., Tuttle, K. R., Idorn, T., Rathor, N., & Lincoff, A. M.
Affiliations
  • Institute of Genetics and Cancer (GB)
  • The University of Texas Southwestern Medical Center (US)
  • Novo Nordisk (Denmark) (DK)
  • University College London (GB)
  • University of Washington (US)
  • Brigham and Women's Hospital (US)
  • Saga University (JP)
  • National Scientific Center "M.D. Strazhesko Institute of Cardiology" (UA)
  • Karolinska Institutet (SE)
  • University of Liverpool (GB)
  • Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
  • Cleveland Clinic Lerner College of Medicine (US)
Corresponding author
Colhoun, Helen M.
Venue
Nature Medicine
Published
2024-05-25
Volume
30
Issue
7
Pages
2058-2066
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4399012115
Cited by
238
References
62
Citations by year
2026: 83 · 2025: 109 · 2024: 46
FWCI
67.86
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, cc-by)
Funders
Novo Nordisk A/S
Topics
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
semaglutide, renal outcomes, obesity, cardiovascular disease, estimated glomerular filtration rate decline, chronic kidney disease, macroalbuminuria, renal replacement therapy, GLP-1 receptor agonists, SELECT trial, non-diabetic patients
MeSH terms
Semaglutide, Aged, Cardiovascular Diseases, Glucagon-Like Peptides, Female, Glomerular Filtration Rate, Humans, Kidney, Kidney Diseases, Male, Middle Aged, Obesity, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. https://app.cochat.ai/papers/10.1038/s41591-024-03015-5
The paper
Colhoun, H. M., Lingvay, I., Brown, P. M., Deanfield, J., Brown-Frandsen, K., Kahn, S. E., Plutzky, J., Node, K., Parkhomenko, A., Rydén, L., Wilding, J. P. H., Mann, J. F. E., Tuttle, K. R., Idorn, T., Rathor, N., & Lincoff, A. M. (2024). Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nature Medicine. https://doi.org/10.1038/s41591-024-03015-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.